Therefore, we propose that AML patients with sporadic CEBPA mutations should be divided into CEBPAsmnon-bZIP, CEBPAsmbZIP, and CEBPAdm for further treatment. This evidence concerns the gene CEBPA and acute myeloid leukemia.